The Company
About Oecona
Oecona provides services within health economic modelling, model adaptations and analyses, market access strategies, development of reimbursement applications and Health Technology Assessment (HTA) dossiers as well as health policy-oriented analyses.
Oecona’s clients are companies in the life science industries both with and without representation in the Nordics. In the light of the steadily changing market access environment in the Nordic countries, Oecona provides guidance on how to effectively interact with the various governmental decision makers when a new product or indication shall be launched.
Gaining market access for pharmaceuticals and medical devices in the Nordics requires insight in both regulations, the roles of the various governmental bodies as well as health economics and governmental affairs.
Our team
Eivind Jørgensen
Managing Director
Eivind Jørgensen is trained as an economist (MPhil, University of Oslo) and has additional training in Health Economics (Diploma of HE, University of Tromsø) and Project Management (Norwegian Business School). He started working with health economic evaluation in AstraZeneca in 2000 and since then, he has been developing health economic models within disease areas such as, but not restricted to, lung cancer, breast cancer, asthma, COPD, Bipolar disease, depression, hypertension, hypercholesterolemia, hepatitis C and migraine. Eivind has an extensive experience with development of reimbursement applications and has submitted between 15 and 20 reimbursement applications to Norwegian authorities. Additionally, he served as the Head of the Health Economics Department in a consulting company and supervised a large number of reimbursement applications. Eivind has held both national and Nordic positions within health economics and market access.
Martin Grøvdal Thoresen
Consultant
Martin holds a European Master in Health Economics and Management (University of Oslo/), specialized in Economic Evaluation in Healthcare. He has knowledge within marketing, economics, health economic modelling, health technology assessment, pharmaceutical industry and policy and strategy development.